Abstract
This new strategic report from Espicom provides a comprehensive review of current and future treatments for major blood cancer therapy areas: chronic lymphocytic leukaemia, chronic myeloid leukaemia, acute myeloid leukaemia, multiple myeloma and non-Hodgkin' s lymphoma.
- Unique market share and 5-year sales forecasts for leading products & pipeline prospects
- A comprehensive examination of major blood cancer therapy areas
- Critical competitive evaluation and scoring of current and future products
THE REPORT COVERS MAJOR BLOOD CANCER AREAS
Chronic lymphocytic leukaemia Chronic myeloid leukaemia Acute myeloid leukaemia Multiple myeloma Non-Hodgkin' s lymphoma
THE MARKET
Risk factors, how the disease affects patients, diagnosis and stages of the disease The market in 2007 and 2012 Growth drivers and dampeners
PATIENT STATISTICS
Prevalence Diagnosis rates Unmet clinical need
CURRENT TREATMENT OPTIONS
Interventions by type Unique five point competitive assessment and scoring of current therapies and companies involved 5-year sales forecasts for key products
R&D: DRUGS IN LATE STAGE DEVELOPMENT
Focus on new classes of drugs and the companies involved Unique competitive assessment and scoring of new therapies and companies involved 5-year sales forecasts for key products from year of launch
Providing…
- Detailed analysis and 5-year forecasts for current leading products by value
- A detailed review and assessment of up and coming products
- Unique product assessment and scoring
- An evaluation of the current understanding of blood cancers
Table of Contents
- Blood Cancers
- US incidence of blood cancers, 2007
- Unmet Medical Need
- New Agents In Development
- New mechanisms of action under investigation for the development of blood cancers:
- Monoclonal antibodies in development for treatment of blood cancers
- Major Players
- 2007
- Market share of players in the worldwide blood cancers market, 2007
- 2012
- Market share of players in the worldwide blood cancers market, 2012
- 2007
- Global Sales
- Estimated and forecast worldwide sales in the treatment of blood cancers (US$ millions)
- Regional breakdown of blood cancer market by sales - 2007 and 2012
- Chronic Lymphocytic Leukaemia
- Background
- Patient Statistics
- Patient model
- Estimated prevalence of CLL in major markets, 2005-2012
- Patient model
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
- Global Market
- Forecast CLL market growth (US$ millions)
- Major players
- Current drugs commonly used in the treatment of CLL
- Major players in CLL by sales - 2007
- Forecast major players in CLL by sales - 2012
- Global Market
- The Drugs
- Current Drugs
- Selected response rates from studies of first line treatment of CLL:
- Fludara
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Fludara sales in CLL by region (US$ millions)
- Forecast Fludara sales in CLL by use (US$ millions)
- Competitor ratio analysis
- Rituxan
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Rituxan sales in CLL by use (US$ millions)
- Forecast Rituxan sales in CLL by region (US$ millions)
- Competitor ratio analysis
- Campath
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Campath sales in CLL by use (US$ millions)
- Competitor ratio analysis
- Agents in Development
- Drugs in development for the treatment of CLL
- Agents in late stage development for CLL:
- Treanda
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Treanda sales in CLL (US$ millions)
- Competitor ratio analysis
- Genasense
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Genasense in CLL efficacy summary:
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Genasense sales in CLL by region (US$ millions):
- Forecast Genasense sales in CLL by use (US$ millions):
- Competitor ratio analysis
- Ofatumumab
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast ofatumumab sales in CLL by region (US$millions):
- Forecast ofatumumab sales in CLL by use (US$millions):
- Competitor ratio analysis
- Alvocidib
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast alvocidib sales in CLL (US$ millions)
- Competitor ratio analysis
- Lumliximab
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast lumiliximab sales in CLL (US$ millions)
- Competitor ratio analysis
- Revlimid
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Revlimid CLL sales by use (US$ millions):
- Forecast Revlimid CLL sales by region (US$ millions):
- Competitor ratio analysis
- Chronic Myeloid Leukaemia
- Background
- Patient Statistics
- Trends in US CML incidence:
- Estimated incidence in worldwide CML prevalence:
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
- Global market
- Forecast worldwide CML market (US$ millions)
- Major players - 2007
- Major players in CML by sales - 2007
- Major players - 2012
- Forecast major players in CLL by sales - 2012
- Global market
- The Drugs
- CML treatment timeline:
- Current drugs
- Current drugs used in the treatment of CML:
- Gleevec/Glivec
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- IRIS study: 18-Month Response Rates Determined by Intent-to-Treat Analysis
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Gleevec sales in CML (US$ millions) - excludes sales in GIST
- Competitor ratio analysis
- Sprycel
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Sprycel CML sales (US$ millions):
- Competitor ratio analysis
- Tasigna
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Tasigna CML sales forecast (US$ millions)
- Competitor ratio analysis
- Agents in Development
- Drugs in development for the treatment of CML:
- Agents in late stage development for CML:
- Bosutinib
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast bosutinib sales in CML (US$ millions)
- Competitor ratio analysis
- Panobinostat
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- MK-0457/ VX 680
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Acute Myeloid Leukaemia
- Background
- French-American-British (FAB) Classification of AML
- WHO AML classification:
- Selected risk factors associated with AML:
- Common chromosomal abnormalities in AML:
- Patient Statistics
- Forecast incidence of AML by region:
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
- Global market
- Forecast worldwide adult AML market
- Major players - 2007
- Major players - 2012
- Forecast major players in AML by sales - 2012
- Global market
- The Drugs
- Treatment naïve patients
- Relapsed & refractory AML
- Current drugs used in the treatment of AML:
- Therapeutic strategies in AML and relapsed/refractory AML:
- Mylotarg
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Summary of response rates in Mylotarg studies:
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Agents in Development
- Agents in late stage development for AML:
- Clolar/Evoltra
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast sales of Clolar/Evoltra in adult AML (US$ millions):
- Competitor ratio analysis
- Cloretazine
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast sales of Cloretazine in AML (US$ millions)
- Competitor ratio analysis
- Zarnestra
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Dacogen
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Dacogen sales in adult AML (US$ millions)
- Competitor ratio analysis
- lestaurtinib
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast lestaurtinib sales in AML (US$ millions)
- Competitor ratio analysis
- midostaurin
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast midostaurin sales in AML (US$ millions)
- Competitor ratio analysis
- tandutinib
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- zosuquidar
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Xanafide
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Xanafide sales in AML (US$ millions)
- Competitor ratio analysis
- Ceplene
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Ceplene sales in AML (US$ millions)
- Competitor ratio analysis
- Background
- Multiple Myeloma
- Background
- Patient Statistics
- Patient model
- Estimated prevalence of multiple myeloma in selected markets
- Patient model
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
- Global market
- Forecast worldwide multiple myeloma market (US$ millions):
- Major players
- Major players in multiple myeloma by sales - 2007
- Major players in multiple myeloma by sales - 2012
- Current drugs used in the treatment of multiple myeloma:
- Global market
- The Drugs
- Thalomid
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Thalomid sales in multiple myeloma (US$ millions)
- Competitor ratio analysis
- Revlimid
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Data summary of MM-009 and MM - 010 studies:
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Front line myeloma comparison:
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Velcade
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Velcade sales in multiple myeloma (US$ millions)
- Competitor ratio analysis
- Agents in Development
- Drugs in development for the treatment of multiple myeloma:
- Agents in late stage development for multiple myeloma:
- Tanespimycin
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast tanespimycin sales in relapsed/refractory multiple myeloma (US$ millions)
- Competitor ratio analysis
- mapatumumab
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Belinostat
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Perifosine
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Carfilzomib
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Non Hodgkin' s Lymphoma
- Background
- Frequency of NHL subtypes in adults:
- 1) B-cell CLL /small lymphocytic lymphoma
- 2) Marginal zone lymphoma
- 3) Lymphoplasmocytic lymphoma (Waldenstrom macroglobulinemia):
- 4) Follicular lymphoma:
- 1) Cutaneous T-cell lymphoma:
- 1) Diffuse large B-cell lymphoma (DL BCL):
- 2) Mantle cell lymphoma:
- 3) Burkitt lymphoma/Burkitt-like lymphoma:
- 4) Precursor B-cell leukaemia/lymphoma
- 1) Anaplastic large T/null-cell lymphoma:
- 2) Precursor T-lymphoblastic lymphoma/leukaemia:
- 3) Peripheral T-cell lymphomas:
- Staging Systems
- Patient Statistics
- Patient model
- Forecast NHL incidence and prevalence (000s)
- Patient model
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
- Global market
- Forecast NHL market (excluding CTCL) - US$ millions
- Forecast CTCL market - US$ millions
- Major players
- Current drugs commonly used in the treatment of NHL
- Major players in NHL by sales - 2007
- Major players in NHL by sales - 2012
- Global market
- The Drugs
- Low Grade or Indolent NHL
- Treatment options in indolent/low-grade NHL:
- Intermediate- and high-grade lymphomas:
- T-cell lymphomas:
- Summary of common therapies in NHL
- Background
- Marketed Agents for use in NHL
- Rituxan
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Rituxan penetration rates, Q3-Q4 2005
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Rituxan sales in NHL indications by region (US$ millions)
- Forecast Rituxan sales in NHL indications by use (US$ millions)
- Competitor ratio analysis
- Fludara
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Fludara sales in NHL indications (US$ millions)
- Competitor ratio analysis
- Bexxar
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Bexxar sales (US$ millions):
- Competitor ratio analysis
- Zevalin
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Zevalin sales (US$ millions)
- Competitor ratio analysis
- Rituxan
- Marketed Agents for Cutatenous T-Cell Lymphoma
- Zolinza
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Zolinza sales in CTCL (US$ millions)
- Competitor ratio analysis
- Agents in Development
- Drugs in development for the treatment of NHL:
- Agents in late stage development for NHL:
- Treanda
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Treanda US sales forecasts in NHL indication (US$ millions)
- Competitor ratio analysis
- ofatumumab
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Phase I/II trial results summary:
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast sales of ofatumumab in NHL by region (US$ millions):
- Forecast sales of ofatumumab in NHL by use (US$ millions):
- Competitor ratio analysis
- galiximab
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast galiximab sales in NHL (US$ millions)
- Competitor ratio analysis
- pixantrone
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast pixantrone NHL sales by region (US$ millions):
- Forecast pixantrone sales in NHL by use (US$ millions)
- Competitor ratio analysis
- Revlimid
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Revlimid sales forecasts in NHL (US$ millions)
- Competitor ratio analysis
- Torisel
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Torisel sales in MCL (US$ millions)
- Competitor ratio analysis
- Velcade
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Velcade sales in MCL (US$ millions)
- Forecast Velcade sales in follicular NHL (excludes MCL) by region (US$ millions)
- Forecast Velcade sales in follicular NHL (excludes MCL) by use (US$ millions)
- Competitor ratio analysis
- Inotuzumab Ozogamicin
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Zolinza
- Agents in Late Stage Development for Cutaneous T-Cell Lymphoma
- Zanliumumab
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast sales of zanolimumab in CTCL (US$ millions)
- Competitor ratio analysis
- belinostat
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast sales of belinostat in CTCL (US$ millions)
- Competitor ratio analysis
- Fodosine
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast sales of Fodosine in CTCL (US$ millions)
- Competitor ratio analysis
- Epratuzumab
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- enzastaurin
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Zanliumumab
- CRA Analysis: AML
- CRA summary
- CRA Analysis: CML
- CRA summary
- CRA Analysis: CLL
- CRA Analysis: Multiple Myeloma
- CRA Summary
- CRA Analysis: NHL
- CRA analysis - NHL
- CRA analysis - NHL (continued)…includes CTCL
- Acronyms
